Inflectra

Infliximab, the active ingredient in Inflectra, is a monoclonal antibody presented as a sterile intravenous solution for infusion use. It targets inflammatory diseases by neutralizing tumor necrosis factor‑alpha and is prescribed for adults with autoimmune conditions. It is indicated for chronic inflammatory disorders and is administered under medical supervision in specialized care settings.

GNH USA supplies Inflectra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics for biologic products.

Inflectra is a TNF‑alpha inhibitor used to treat several chronic inflammatory diseases. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Crohn's disease: induces and maintains remission of intestinal inflammation. - Ulcerative colitis: helps achieve clinical remission and mucosal healing. - Ankylosing spondylitis: alleviates spinal pain and improves mobility. - Psoriatic arthritis: decreases joint swelling and skin lesions. - Plaque psoriasis: clears skin plaques and reduces scaling.

Inflectra may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Infusion‑related reactions: flushing, chills, or shortness of breath during administration. - Headache: mild to moderate intensity, often transient. - Nausea: occasional gastrointestinal upset. - Infections: upper respiratory or urinary tract infections.

Serious or Rare Side Effects: - Severe infections: including opportunistic bacterial, fungal, or viral infections. - Reactivation of latent tuberculosis: may progress to active disease. - Demyelinating disorders: new or worsening neurologic symptoms such as optic neuritis.

Before starting Inflectra, clinicians should evaluate patients for factors that could increase risk of complications. - Screen for active infections: perform TB, hepatitis B/C, and HIV testing. - Monitor for latent tuberculosis: consider prophylactic therapy if indicated. - Assess cardiac function: avoid in patients with moderate to severe heart failure. - Update vaccinations: administer required non‑live vaccines before therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Inflectra can interact with other agents that affect immune function or infection risk.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection; avoid concurrent use. - Antifungal azoles (e.g., ketoconazole): can increase serum infliximab levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Methotrexate or other immunosuppressants: heightened infection susceptibility; monitor labs. - Systemic corticosteroids: additive immunosuppression; watch for signs of infection. - NSAIDs: may increase gastrointestinal bleeding risk; assess patient tolerance.